Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 1/2
2(100.0%)
2Total
Phase 1/2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT07897448Phase 1/2Not Yet Recruiting

A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)

Role: lead

NCT07876856Phase 1/2Not Yet Recruiting

A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)

Role: collaborator

All 2 trials loaded